Search - tctmd.com

Displaying 321 - 340 of 520

Sort: Relevancy | Date

ACC 2018, Day Three: Gout, Hypertension, and Diabetes Dominate Opening Late Breaker

News Conference News ACC 2018

ACC 2018, Day Three: Gout, Hypertension, Diabetes, PFO Closure, DAPT, NOAC Reversal, and More

Shelley Wood

March 12, 2018

News Conference News ACC 2018

TREAT: No Major Bleeds With Ticagrelor in ACS Patients After Fibrinolysis

Shelley Wood

March 11, 2018

News Daily News

‘High Index of Suspicion’ First Step in Successful Management of SCAD

Michael O'Riordan

February 27, 2018

News Daily News

Compliance With Preventive Drugs After CABG, PCI Found Lacking in Clinical Trials

Todd Neale

February 06, 2018

News Daily News

Multivessel Disease Patients See Benefits of Long-term Ticagrelor: PEGASUS-TIMI 54 Analysis

Yael L. Maxwell

January 31, 2018

News Daily News

High Rate of Clinical Events at 6 Months for Ischemic CVD Patients

Michael O'Riordan

January 19, 2018

News Daily News

De-escalating DAPT to a Clopidogrel-Based Strategy After PCI for ACS Gets Boost in TOPIC-VASP

Yael L. Maxwell

January 04, 2018

News Daily News

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Shelley Wood

December 26, 2017

News Daily News

Hospital Readmission Patterns Post-MI in China Differ Markedly From in the US

Yael L. Maxwell

December 07, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2017

Shelley Wood

November 29, 2017

News Features

Trajectory Unknown: How ORBITA Lands in Clinical Practice Still Up for Debate

Michael O'Riordan

November 27, 2017

News Daily News

Radial Access Best for PCI Following Thrombolysis in STEMI

Michael O'Riordan

November 27, 2017

News Conference News AHA 2017

RE-DUAL PCI Findings Consistent Across Key Subgroups

Todd Neale

November 16, 2017

News Conference News TCT 2017

Shortened DAPT Durations Appear Safe for Patients With ACS Implanted With DES

Todd Neale

November 01, 2017

News Opinion Editor's Corner TCT 2017

Live From Denver: TCT 2017, Day Three

Shelley Wood

November 01, 2017

News Daily News

Lesion Complexity and Patient Risk: A Balancing Act for DAPT Duration

Yael L. Maxwell

October 23, 2017

News Daily News

Study Questions Incremental Benefit of Beta-Blockers After Acute MI

Michael O'Riordan

September 21, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2017

Caitlin E. Cox

August 31, 2017

News Conference News ESC 2017

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

Michael O'Riordan

August 29, 2017

News Conference News ESC 2017

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

Michael O'Riordan

August 28, 2017

Advertisement

ACC 2018, Day Three: Gout, Hypertension, Diabetes, PFO Closure, DAPT, NOAC Reversal, and More

TREAT: No Major Bleeds With Ticagrelor in ACS Patients After Fibrinolysis

‘High Index of Suspicion’ First Step in Successful Management of SCAD

Compliance With Preventive Drugs After CABG, PCI Found Lacking in Clinical Trials

Multivessel Disease Patients See Benefits of Long-term Ticagrelor: PEGASUS-TIMI 54 Analysis

High Rate of Clinical Events at 6 Months for Ischemic CVD Patients

De-escalating DAPT to a Clopidogrel-Based Strategy After PCI for ACS Gets Boost in TOPIC-VASP

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Hospital Readmission Patterns Post-MI in China Differ Markedly From in the US

TCTMD’s Top 10 Most Popular Stories for November 2017

Trajectory Unknown: How ORBITA Lands in Clinical Practice Still Up for Debate

Radial Access Best for PCI Following Thrombolysis in STEMI

RE-DUAL PCI Findings Consistent Across Key Subgroups

Shortened DAPT Durations Appear Safe for Patients With ACS Implanted With DES

Live From Denver: TCT 2017, Day Three

Lesion Complexity and Patient Risk: A Balancing Act for DAPT Duration

Study Questions Incremental Benefit of Beta-Blockers After Acute MI

TCTMD’s Top 10 Most Popular Stories for August 2017

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content